Abstract
The current state of knowledge regarding the safety of measles, mumps and rubella vaccine (MMR) is reviewed. Although there are known adverse reactions to the vaccine, the majority are relatively minor and have no long term consequences, and those that do have long term consequences are extremely rare. Contraindications, known adverse reactions that may follow MMR immunisation, publicised adverse events for which a causal association with MMR has not been established, and the complications that may follow an infection with wild-type measles, mumps or rubella, are discussed. The article also discusses, with examples, the misleading information that can be obtained on the internet and in the public press.
It is vital that the general public have an understanding of the great benefits and low risks associated with the use of MMR vaccine, because it is important that they consent to the administration of MMR vaccine to their children in order to ensure the success of universal immunisation programmes and the control of measles, mumps and rubella. Therefore, it becomes increasingly important for health professionals to use innovative education methods to promote immunisation and counteract the incorrect and misleading information that is readily available on the internet and in the media.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Last JM. Public health and human ecology. 2nd rev. Stanford (CT): Appleton and Lange, 1998: 365–75
Mausner JS, Kramer S. Epidemiology: an introductory text. 2nd rev. Philadelphia (PA): W B Saunders, 1985: 180–7
Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental? Lancet 1998; 351: 611–2
Lee JW, Melgaard B, Clements CJC, et al. Autism, inflammatory bowel disease and MMR vaccine. Lancet 1998; 351: 905
Advisory Committee on Immunization Practices. Measles, mumps and rubella — vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1998 May 22; 47: RR8 19–57
James JM, Burks AW, Roberson PK, et al. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332: 1262–6
Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993; 341: 979–82
Duclos P, Ward BJ. Measles vaccines: a review of adverse events. Drug Saf 1998; 19: 435–54
Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Mortimer EA, editors. Vaccines. 2nd rev. Philadelphia: WB Saunders, 1994: 252
Institute of Medicine. Evidence concerning rubella vaccines and arthritis, radiculoneuritis, and thrombocytopenic purpura. In: Howson CP, Howe CJ, Fineberg HV, editors. Adverse effects of pertussis and rubella vaccines. Washington DC: National Academy Press, 1991: 187–205
da Silva CM, Salisbury DM, de Quadros CA. Measles vaccination and Guillain-Barré syndrome. Lancet 1997; 349: 14–6
Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoidnodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637–41
Pebody RG, Paunio M, Ruutu P. Crohn’s disease has not increased in 1998 Finland. BMJ 1998; 316: 1745–6
Miller E, Waight P. Measles, measles vaccination, and Crohn’s disease. Second immunisation has not affected incidence in England. BMJ 1998; 316: 1745
Amin J, McIntyre PB, Heath TC. Measles vaccine, inflammatory bowel disease and pervasive developmental disorder: is there a cause for concern? Communic Dis Intell 1998; 22(4): 58–9
Afzal MA, Minor PD, Begley J, et al. Absence of measles-virus genome in inflammatory bowel disease. Lancet 1998; 351: 646–7
Sinclair L. Autism, inflammatory bowel disease and MMR vaccine. Lancet 1998; 351: 1355
Peltola H, Heinonen OP. Frequency of true adverse reactions to measles mumps-rubella vaccine: a double-blind placebo-controlled trial in twins. Lancet 1986; I: 939–42
Lerman SJ, Bollinger M, Brunken JM. Clinical and serological evaluation of measles, mumps, and rubella (HPV-77: DE-5 and RA 27/3) virus vaccines, singly and in combination. Pediatrics 1981; 68: 18–22
Mackay I. Virology down under: measles, mumps and rubella [internet web page]. http://www.im.ac.cn/vdu/mmr.htm [accessed 1999 Sep 20]
Leading Edge International Research Group. Production of mass behavioral and neurological problems using vaccination to increase social control [internet web page]. http://trufax.org/m3v2/vacc2.html [accessed 1999 Sep 20]
Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two dose immunization program. N Engl J Med 1994; 331: 1397–402
Migasena S, Simasathien S, Samakoses R, et al. Adverse impact of infections on antibody response to measles vaccination. Vaccine 1998; 16(6): 647–52
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
West, R., Roberts, P.M. Measles, Mumps and Rubella Vaccine. BioDrugs 12, 423–429 (1999). https://doi.org/10.2165/00063030-199912060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199912060-00002